Licensing Opportunities

IONTAS wishes to see the benefits of its technologies exploited as widely as possible. To this end we have a range of technologies arising from research at our facilities available for licensing.

Where technologies are licenced to third parties, we offer a range of support to ensure the effective implementation of transferred technologies into our partners facilities. Furthermore, consultancy can be offered to support specific requirements or further development of our platforms.

Currently IONTAS offers three licencing opportunities

1)    Mammalian display – An antibody discovery platform that generates vast libraries of fully human IgG on the surface of a mammalian cell. The platform is designed so one antibody is expressed per cell, allowing for screening of IgG using FACS thereby increasing throughput to millions of fully human IgG’s in a hours. The IgG molecules can be a screened for binding and presentation level on the surface of the mammalian cells. The presentation level on the surface of the mammalian cells has been shown to strongly correlate with a reduced propensity to aggregate and good developability.

The platform can be transferred to a Partners facility and training/support is  offered at either Partner sites or within IONTAS’s facilities. The licencing of mammalian display also encompasses improvements to the platform and we welcome collaborative developments to address any specific need of our partners.

2)    Naïve phage display libraries – using the insight from Maria Pajuelo, John McCafferty and their development team libraries can be designed that address our Partners needs. These libraries can be produced as naïve human scFv or Fab repertoires or llama VHH repertoires. Library sizes vary dependent on the antibody format but a expectation of sizes in excess of 10e10 is routine.

As with mammalian display, training and support are offered to ensure the libraries are functional  and successful in our Partner facilities

3)    Triple Vector – This technology facilitates the conversion antibody fragments into full length IgG or Fc fusion proteins, typically a bottleneck in antibody discovery. Moreover, for some antibody fragments the conversion to Fc fusion proteins result in loss of activity. To circumvent these drawbacks, the triple vector technology comprises a vector that contains the elements necessary to produce soluble antibody fragments in bacteria, and mammalian cells. Ultimately the selection of immunological effector function bearing bivalent molecules, bypassing the cloning into mammalian expression vectors, will accelerate the drug discovery process.

Further information on our licencing opportunities can be supplied by emailing info@iontas.co.uk